Elevated osteoprotegerin is associated with all-cause mortality in CKD stage 4 and 5 patients in addition to vascular calcification

Nephrology Dialysis Transplantation

Volumn 24, Issue 10, 2009, Pages 3157-3162

  Sigrist, Mhairi K ^a,b   Levin, Adeera ^b   Er, Lee ^b   McIntyre, Chris W ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

CKD; Mortality; Osteoprotegerin; Vascular calcification

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; FETUIN A; OSTEOPROTEGERIN;

ADULT; AGED; ARTICLE; BLOOD VESSEL CALCIFICATION; BLOOD VESSEL INJURY; CHRONIC KIDNEY DISEASE; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEMODIALYSIS; HUMAN; HYPOALBUMINEMIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIDETECTOR COMPUTED TOMOGRAPHY; PERITONEAL DIALYSIS; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEX DIFFERENCE; SUPERFICIAL FEMORAL ARTERY; SURVIVAL;

C-REACTIVE PROTEIN; CALCINOSIS; CAUSE OF DEATH; CHRONIC DISEASE; FEMALE; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; OSTEOPROTEGERIN; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TIME FACTORS; VASCULAR DISEASES;

EID: 70349484205     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp253     Document Type: Article

References (30)

1. USRDS USRDS. Mortality & causes of death. USRDS 2002 Annual Data Report. Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2002
2. Kalantar-Zadeh K, Block G, Humphreys MH et al. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003; 63: 793-808 (Pubitemid 36315558)
3. Sigrist MK, Taal MW, Bungay P et al. Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease. Clin J Am Soc Nephrol 2007; 2: 1241-1248
4. Shroff RC, Shah V, Hiorns MP et al. The circulating calcification inhibitors, fetuin-A and osteoprotegerin, but not Matrix Gla protein, are associated with vascular stiffness and calcification in children on dialysis. Nephrol Dial Transplant 2008; 23: 3263-3271
5. Simonet WS, Lacey DL, Dunstan CR et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89: 309-319
6. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003; 423: 337-342
7. Shin JY, Shin YG, Chung CH. Elevated serum osteoprotegerin levels are associated with vascular endothelial dysfunction in type 2 diabetes. Diabetes Care 2006; 29: 1664-1666
8. Anand DV, Lahiri A, Lim E et al. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll Cardiol 2006; 47: 1850-1857
9. Sandberg WJ, Yndestad A, Oie E et al. Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization. Arterioscler Thromb Vasc Biol 2006; 26: 857-863
10. Nitta K, Akiba T, Uchida K et al. Serum osteoprotegerin levels and the extent of vascular calcification in haemodialysis patients. Nephrol Dial Transplant 2004; 19: 1886-1889
11. Jono S, Ikari Y, Shioi A et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002; 106: 1192-1194
12. Omland T, Ueland T, Jansson AM et al. Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. J Am Coll Cardiol 2008; 51: 627-633
13. Hjelmesaeth J, Ueland T, Flyvbjerg A et al. Early posttransplant serum osteoprotegerin levels predict long-term (8-year) patient survival and cardiovascular death in renal transplant patients. J Am Soc Nephrol 2006; 17: 1746-1754
14. Morena M, Terrier N, Jaussent I et al. Plasma osteoprotegerin is associated with mortality in hemodialysis patients. J Am Soc Nephrol 2006; 17: 262-270
15. Block GA, Raggi P, Bellasi A et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007; 3: 3
16. London GM, Guerin AP, Marchais SJ et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731-1740
17. Barreto DV, Barreto FC, Carvalho AB et al. Coronary calcification in hemodialysis patients: the contribution of traditional and uremia-related risk factors. Kidney Int 2005; 67: 1576-1582
18. Jean G, Bresson E, Terrat JC et al. Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences. Nephrol Dial Transplant 2009; 24: 948-955.
19. Moe SM, Reslerova M, Ketteler M et al. Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). Kidney Int 2005; 67: 2295-2304
20. Browner WS, Lui LY, Cummings SR. Associations of serum osteo-protegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 2001; 86: 631-637
21. Kiechl S, Schett G, Wenning G et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004; 109: 2175-2180
22. Avignon A, Sultan A, Piot C et al. Osteoprotegerin: a novel independent marker for silent myocardial ischemia in asymptomatic diabetic patients. Diabetes Care 2007; 30: 2934-2939
23. Omland T, Drazner MH, Ueland T et al. Plasma osteoprotegerin levels in the general population: relation to indices of left ventricular structure and function. Hypertension 2007; 49: 1392-1398
24. Pritzker LB, Scatena M, Giachelli CM. The role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand in human microvascular endothelial cell survival. Mol Biol Cell 2004; 15: 2834-2841
25. Wexler L, Brundage B, Crouse J et al. Coronary artery calcification: pathophysiology, epidemiology, imaging methods, and clinical implications. A statement for health professionals from the American Heart Association. Writing Group. Circulation 1996; 94: 1175-1192
26. Zannettino AC, Holding CA, Diamond Pet al. Osteoprotegerin (OPG) is localizedto the Weibel-Palade bodiesofhuman vascular endothelial cells and is physically associated with von Willebrand factor. J Cell Physiol 2005; 204: 714-723
27. Bradbury BD, Fissell RB, Albert JM et al.Predictorsofearly mortality among incident US hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Clin J Am Soc Nephrol 2007; 2: 89-99
28. Ketteler M, Bongartz P, Westenfeld R et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 2003; 361: 827-833
29. Hermans MM, Brandenburg V, Ketteler M et al. Study on the relationship of serum fetuin-A concentration with aortic stiffness in patients on dialysis. Nephrol Dial Transplant 2006; 21: 1293-1299
30. Ansell D, Feehally J, Feest TG et al. UK Renal Registry Report UK Renal Registry, Bristol, UK 2007; Available at: http://www.renalreg.com/reports/renal- registry-reports/2007/